Jun 01, 2024 8:00am EDT Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response
May 31, 2024 4:05pm EDT Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024
May 29, 2024 7:00am EDT Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma
May 08, 2024 7:00am EDT Immunocore reports first quarter financial results and provides a business update
Feb 28, 2024 7:34am EST Immunocore reports fourth quarter and full year 2023 financial results and provides a business update